Merit Functional Foods placed into receivership

Mar 03, 2023

The Winnipeg-based plant protein company was placed into receivership on Wednesday, March 1st.

The company's lenders Farm Credit Canada and Export Development Canada filed an application for the appointment of a receiver.

In 2019, Merit Functional Foods Corporation was developed as a joint venture between Burcon ( a global technology leader in the development of plant-based proteins) and three other investors.

Construction began that fall on the projected $150 million, 94-thousand-square-foot production facility to produce novel pea and canola protein ingredients for use in food and beverages.

Burcon NutraScience Corporation says this ( the receivership ) was an anticipated step and does not alter its plan to acquire Merit's business.

In a press release on the company website, they note they are in active discussions with PricewaterhouseCoopers Inc the appointed receiver.

Merit Functional Foods co-CEO Ryan Bracken says that while their proteins have been formulated into countless products globally, they couldn’t quite get to the level of cashflow needed to operate the business profitably, quick enough.

He also referenced some pandemic-related challenges that led to the company’s closure.

Source : Pembinavalley online

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.